Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1

Sara M Thomasy, Christine C. Lim, Christopher M. Reilly, Philip H Kass, Michael R. Lappin, David J Maggs

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective-To evaluate orally administered famciclovir for treatment of cats with experimentally induced disease attributable to feline herpesvirus type-1 (FHV-1). Animals-16 nonvaccinated specific-pathogen-free cats. Procedures-Cats were treated orally with famciclovir (90 mg/kg; n = 10) or a similar volume of lactose (400 mg; 6) 3 times/d for 21 days. Cats were inoculated with FHV-1 and administered the first treatment dose on day 0. Disease score; weight; results of urinalysis, serum biochemical analysis, and CBC; histologic conjunctivitis score; herpetic DNA shedding; goblet cell density; anti-FHV-1 antibody concentration; and plasma penciclovir concentration were measured. Results-On days 4 to 18 following inoculation, disease scores were lower in famciclovirtreated cats than in lactose-treated cats. Lactose-treated cats decreased in weight during the first 7 days after inoculation, but famciclovir-treated cats increased in weight throughout the study. Percentage change in weight was greater in famciclovir-treated cats on days 7 and 14 than in lactose-treated cats. Serum globulin concentration was lower on days 3 through 9, conjunctivitis histologic score was lower on day 14, herpetic DNA was shed less frequently throughout the study, goblet cell density was greater on day 21, and circulating anti-FHV-1 antibody concentration at study end was lower in famciclovir-treated cats, compared with these measurements in lactose-treated cats. Approximate peak plasma penciclovir concentration was 2.0 μg/mL. Conclusions and Clinical Relevance-Famciclovir administration improved outcomes for systemic, ophthalmic, clinicopathologic, virologic, and histologic variables in cats experimentally infected with FHV-1. Adjunctive topical mucinomimetic and antimicrobial treatments may also be necessary. (Am J Vet Res 2011;72:85-95).

Original languageEnglish (US)
Pages (from-to)85-95
Number of pages11
JournalAmerican Journal of Veterinary Research
Volume72
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Felid herpesvirus 1
Herpesviridae
Felidae
Cats
cats
Lactose
lactose
Weights and Measures
conjunctivitis
Conjunctivitis
Goblet Cells
goblet cells
famciclovir
Cell Count
Specific Pathogen-Free Organisms
Serum Globulins
antibodies
Urinalysis
urinalysis
Antibodies

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1. / Thomasy, Sara M; Lim, Christine C.; Reilly, Christopher M.; Kass, Philip H; Lappin, Michael R.; Maggs, David J.

In: American Journal of Veterinary Research, Vol. 72, No. 1, 01.2011, p. 85-95.

Research output: Contribution to journalArticle

@article{5d32eb805e5347208c5431aba58ee834,
title = "Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1",
abstract = "Objective-To evaluate orally administered famciclovir for treatment of cats with experimentally induced disease attributable to feline herpesvirus type-1 (FHV-1). Animals-16 nonvaccinated specific-pathogen-free cats. Procedures-Cats were treated orally with famciclovir (90 mg/kg; n = 10) or a similar volume of lactose (400 mg; 6) 3 times/d for 21 days. Cats were inoculated with FHV-1 and administered the first treatment dose on day 0. Disease score; weight; results of urinalysis, serum biochemical analysis, and CBC; histologic conjunctivitis score; herpetic DNA shedding; goblet cell density; anti-FHV-1 antibody concentration; and plasma penciclovir concentration were measured. Results-On days 4 to 18 following inoculation, disease scores were lower in famciclovirtreated cats than in lactose-treated cats. Lactose-treated cats decreased in weight during the first 7 days after inoculation, but famciclovir-treated cats increased in weight throughout the study. Percentage change in weight was greater in famciclovir-treated cats on days 7 and 14 than in lactose-treated cats. Serum globulin concentration was lower on days 3 through 9, conjunctivitis histologic score was lower on day 14, herpetic DNA was shed less frequently throughout the study, goblet cell density was greater on day 21, and circulating anti-FHV-1 antibody concentration at study end was lower in famciclovir-treated cats, compared with these measurements in lactose-treated cats. Approximate peak plasma penciclovir concentration was 2.0 μg/mL. Conclusions and Clinical Relevance-Famciclovir administration improved outcomes for systemic, ophthalmic, clinicopathologic, virologic, and histologic variables in cats experimentally infected with FHV-1. Adjunctive topical mucinomimetic and antimicrobial treatments may also be necessary. (Am J Vet Res 2011;72:85-95).",
author = "Thomasy, {Sara M} and Lim, {Christine C.} and Reilly, {Christopher M.} and Kass, {Philip H} and Lappin, {Michael R.} and Maggs, {David J}",
year = "2011",
month = "1",
doi = "10.2460/ajvr.72.1.85",
language = "English (US)",
volume = "72",
pages = "85--95",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "1",

}

TY - JOUR

T1 - Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1

AU - Thomasy, Sara M

AU - Lim, Christine C.

AU - Reilly, Christopher M.

AU - Kass, Philip H

AU - Lappin, Michael R.

AU - Maggs, David J

PY - 2011/1

Y1 - 2011/1

N2 - Objective-To evaluate orally administered famciclovir for treatment of cats with experimentally induced disease attributable to feline herpesvirus type-1 (FHV-1). Animals-16 nonvaccinated specific-pathogen-free cats. Procedures-Cats were treated orally with famciclovir (90 mg/kg; n = 10) or a similar volume of lactose (400 mg; 6) 3 times/d for 21 days. Cats were inoculated with FHV-1 and administered the first treatment dose on day 0. Disease score; weight; results of urinalysis, serum biochemical analysis, and CBC; histologic conjunctivitis score; herpetic DNA shedding; goblet cell density; anti-FHV-1 antibody concentration; and plasma penciclovir concentration were measured. Results-On days 4 to 18 following inoculation, disease scores were lower in famciclovirtreated cats than in lactose-treated cats. Lactose-treated cats decreased in weight during the first 7 days after inoculation, but famciclovir-treated cats increased in weight throughout the study. Percentage change in weight was greater in famciclovir-treated cats on days 7 and 14 than in lactose-treated cats. Serum globulin concentration was lower on days 3 through 9, conjunctivitis histologic score was lower on day 14, herpetic DNA was shed less frequently throughout the study, goblet cell density was greater on day 21, and circulating anti-FHV-1 antibody concentration at study end was lower in famciclovir-treated cats, compared with these measurements in lactose-treated cats. Approximate peak plasma penciclovir concentration was 2.0 μg/mL. Conclusions and Clinical Relevance-Famciclovir administration improved outcomes for systemic, ophthalmic, clinicopathologic, virologic, and histologic variables in cats experimentally infected with FHV-1. Adjunctive topical mucinomimetic and antimicrobial treatments may also be necessary. (Am J Vet Res 2011;72:85-95).

AB - Objective-To evaluate orally administered famciclovir for treatment of cats with experimentally induced disease attributable to feline herpesvirus type-1 (FHV-1). Animals-16 nonvaccinated specific-pathogen-free cats. Procedures-Cats were treated orally with famciclovir (90 mg/kg; n = 10) or a similar volume of lactose (400 mg; 6) 3 times/d for 21 days. Cats were inoculated with FHV-1 and administered the first treatment dose on day 0. Disease score; weight; results of urinalysis, serum biochemical analysis, and CBC; histologic conjunctivitis score; herpetic DNA shedding; goblet cell density; anti-FHV-1 antibody concentration; and plasma penciclovir concentration were measured. Results-On days 4 to 18 following inoculation, disease scores were lower in famciclovirtreated cats than in lactose-treated cats. Lactose-treated cats decreased in weight during the first 7 days after inoculation, but famciclovir-treated cats increased in weight throughout the study. Percentage change in weight was greater in famciclovir-treated cats on days 7 and 14 than in lactose-treated cats. Serum globulin concentration was lower on days 3 through 9, conjunctivitis histologic score was lower on day 14, herpetic DNA was shed less frequently throughout the study, goblet cell density was greater on day 21, and circulating anti-FHV-1 antibody concentration at study end was lower in famciclovir-treated cats, compared with these measurements in lactose-treated cats. Approximate peak plasma penciclovir concentration was 2.0 μg/mL. Conclusions and Clinical Relevance-Famciclovir administration improved outcomes for systemic, ophthalmic, clinicopathologic, virologic, and histologic variables in cats experimentally infected with FHV-1. Adjunctive topical mucinomimetic and antimicrobial treatments may also be necessary. (Am J Vet Res 2011;72:85-95).

UR - http://www.scopus.com/inward/record.url?scp=78651452289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651452289&partnerID=8YFLogxK

U2 - 10.2460/ajvr.72.1.85

DO - 10.2460/ajvr.72.1.85

M3 - Article

C2 - 21194340

AN - SCOPUS:78651452289

VL - 72

SP - 85

EP - 95

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 1

ER -